Title

Molecular docking analysis of Bcl-2 with phytocompounds

Authors

Chandrasekaran Kirubhanand¹, Jayaraman Selvaraj², Umapathy Vidhya Rekha³, Veeraraghavan Vishnupriya², Venkatachalam Sivabalan⁴, Mathayan Manikannan⁵, Devarajan Nalini⁶, Periyasamy Vijayalakshmi⁷, Manikkam Rajalakshmi⁷, Rajagopal Ponnulakshmi⁸,*

Affiliation

¹Department of Anatomy, All India Institute of Medical Sciences, Nagpur, India; ²Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai - 600 077, India; ³Department of Public Health Dentistry, Sree Balaji Dental College and Hospital, Pallikaranai, Chennai-600 100, India; ⁴Department of Biochemistry, KSR Institute of Dental Science and Research, Tiruchengode-637215. Tamil Nadu, India; ⁵Centre for Drug Discovery and Development, Sathyabama Institute of Science and Technology, Chennai-600 119, India; ⁶Central Research Laboratory, Meenakshmi Ammal Dental College, Meenakshi Academy of Higher Education and Research (Deemed to be University), Chennai-600 095, India; ⁷DBT-BIF Centre, PG & Research Department of Biotechnology & Bioinformatics, Holy Cross College (Autonomous), Trichy, Tamil Nadu, India; ⁸Central Research Laboratory, Meenakshi Academy of Higher Education and Research (Deemed to be University), West K. K. Nagar, Chennai-600 078, India
 

Email

Dr. Rajagopal Ponnulakshmi - E-mail: ramgslaks@gmail.com; Corresponding author*

Article Type

Research Article

Date

Received March 3, 2020; Revised April 30, 2020; Accepted May 9, 2020; Published June 30, 2020

The Bcl-2 protein is liked in several cancers and drug resistance to therapy is also known in this context. There are many Bcl-2 inhibitors under clinical trials. It is of further interest to design new Bcl2 inhibitors from phyto compounds such as artesunate, bruceantin, maytansin, Salvicine, indicine N-oxide, kamebanin and oxyacanthine. We report the optimal binding features of these compounds with Bcl-2 for further consideration towards in vitro and in vivo validation.

Keywords

Breast cancer, bioactive compounds, Bcl-2, molecular docking

Citation

Kirubhaanad et al. Bioinformation 16(6): 468-473 (2020)

Edited by

P Kangueane

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.